Citius Pharmaceuticals Income Taxes 2013-2024 | CTXR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Citius Pharmaceuticals income taxes from 2013 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Citius Pharmaceuticals income taxes from 2013 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$74.8B
Chugai Pharmaceutical (CHGCY)	$70.2B
Takeda Pharmaceutical (TAK)	$41.1B
Sandoz Group AG (SDZNY)	$19.6B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$17.3B
United Therapeutics (UTHR)	$16B
Neurocrine Biosciences (NBIX)	$14.5B
Summit Therapeutics (SMMT)	$14B
Shionogi (SGIOY)	$12.1B
Orion OYJ (ORINY)	$7.2B
Stevanato Group S.p.A (STVN)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Corcept Therapeutics (CORT)	$5.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.5B
Grifols, S.A (GRFS)	$5B
Ionis Pharmaceuticals (IONS)	$5B
Crinetics Pharmaceuticals (CRNX)	$3.5B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Recursion Pharmaceuticals (RXRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.2B
Soleno Therapeutics (SLNO)	$2B
Centessa Pharmaceuticals (CNTA)	$2B
Hypermarcas (HYPMY)	$1.9B
Indivior (INDV)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Evotec AG (EVO)	$1.5B
Dyne Therapeutics (DYN)	$1.4B
Xencor (XNCR)	$1.3B